Drug intelligence / Profile preview

REGN17092

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

REGN17092 is a next-generation monoclonal antibody developed by Regeneron Pharmaceuticals for the prevention and treatment of COVID-19 (SARS-CoV-2 infection). It was designed to maintain potency against emerging variants of concern that escaped earlier antibody treatments like casirivimab and imdevimab. The antibody targets the spike protein of the SARS-CoV-2 virus, preventing viral entry into host cells. It has been evaluated in Phase 1 clinical trials for safety, tolerability, and pharmacokinetics in healthy volunteers.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on REGN17092.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN17092.

Explore the full profile